'Mad Money Lightning Round': Wells Fargo Too Risky

To see the full "Mad Money" Recap, please click here .


NEW YORK ( TheStreet) -- Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Friday evening.

Linn Energy ( LINE): "That company is good and the yield is fine, but let's take some profits. I don't want to get hurt."

Raytheon ( RTN): "I'm worried that the defense budget needs to shrink. Raytheon is very cheap, but if the government is cutting, you don't want to be there."

Gilead Sciences ( GILD): "The sentiment is improving. I think Gilead works, but it's not best of breed anymore."

Yanzhou Coal Mining ( YZC): "I do not trust the Chinese stock market. I only recommend Baidu.com ( BIDU). If I want coal, I want Peabody Energy ( BTU), not yours. "

Wells Fargo ( WFC): "Wells Fargo is too hard. It's too risky for me. I prefer JPMorgan Chase ( JPM)."

--Written by Scott Rutt in Washington, D.C.

To contact the writer of this article, click here: Scott Rutt.

To follow the writer on Twitter, go to http://twitter.com/scottrutt.

To submit a news tip, send an email to: tips@thestreet.com.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

*For all you home-gamers, a 'mon-back opportunity means Cramer would back up the figurative truck and load up on a stock.

Want more Cramer? Check out Jim's rules and commandments for investing by clicking here.

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside